All In Biotech

Drug Trial Radar · NCT06675864

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Jun 14, 2030

Study completion Jun 14, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

Conditions

  • Progressive Multiple Sclerosis

Interventions

  • rapcabtagene autoleucel (YTB323)Biological

    CAR-T cell suspension for intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs)Time frame: Day 1 through Year 2

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Québec, Quebec, Canada

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nancy, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Spain

  • Novartis Investigative Site

    Bern, Switzerland

  • Novartis Investigative Site

    Lausanne, Switzerland

  • Novartis Investigative Site

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.